It remains controversial whether H. l~ylori plays an important role in nonulcer dyspepsia (1-3). We therefore read with interest the recent report by McCarthy el al (4). Patients with nonulcer dyspepsia were treated with three dilfcrent regimes to eradicate H.
lO'lori. Importantly,. it was found at one year that patients who were cured of their infection had significantly lower symptom scores than patients with persisting infection. They conclude, as stated in their abstract, that "'These results suggest that Helicohacter Fyh)ri plays an important role in the symptoms of nonulccr dyspepsia." While the authors may be correct, we believe that the methodological limitations of their study need to be appreei~,ted before drawing any firm conclusions.
One of the major problems in the McCarthy study was the lack of random allocation of treatments.
There is now ample empiric evidence that nonrandomized studies yield larger estimates of therapeutic efficacy than properly randomized trials (5) . which could in part account for the promising results reported by McCarthy et al. A further point is that patients who fail to respond to curative therapy may bc quite different from those who do respond (6) . For example, it is conceivablc that those with more severe nonulcer dyspepsia symptoms are less likely to respond to anti-H, i~ylori regimens becat, se the drugs
induce more ~a, tromtestmal side efl'ects and hence lead to reduced compliance. Merely comparing those who were successfully treated with those who failed treatment is thus potentially misleading. The lack of a placebo control group is of equal concern because we just do not know whether a placebo group would havc performed as well as the curative therapy group over the long term (6 
